Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALM1 | P0DP23 | 1/20 | 0.55 |
| ▸ | IGF1R | P08069 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27241091 | 0.98 | CALM1 (0.53) | CALM1IGF1RALOX15ALOX5TAAR1 | |
| SCHEMBL11044754 | 0.98 | CALM1 (0.53) | CALM1IGF1RALOX15ALOX5TAAR1 | |
| SCHEMBL1272900 | 0.94 | CALM1 (0.56) | CALM1IGF1RALOX15ALOX5TAAR1 | |
| Hydrochloric Acid SCHEMBL6614288 | 0.93 | CALM1 (0.55) | CALM1IGF1RALOX15ALOX5TAAR1 | |
| SCHEMBL911097 | 0.86 | TAAR1 (0.55) | CALM1ALOX15TAAR1CA12CA1 | |
| SCHEMBL4254058 | 0.84 | CALM1 (0.72) | CALM1IGF1RALOX15ALOX5TAAR1 | |
| SCHEMBL8196325 | 0.82 | CHRM2 (0.53) | CALM1IGF1RALOX15CA12CA1 | |
| SCHEMBL12549249 | 0.82 | NQO1 (0.48) | L3MBTL1 | |
| SCHEMBL17400406 | 0.82 | CALM1 (0.69) | CALM1IGF1RALOX15ALOX5TAAR1 | |
| SCHEMBL11007798 | 0.82 | CALM1 (0.69) | CALM1IGF1RALOX15ALOX5TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119118910-A | Compounds for specific labelling of Tau proteins | 北京师范大学 | 2024-12-13 | — | — | CN | disclosed |
| US-12030835-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-09 | — | — | US | disclosed |
| US-20220213026-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-07-07 | — | — | US | disclosed |
| EP-1694619-B1 | LIQUID-CRYSTAL COMPOSITIONS COMPRISING CHIRAL COMPOUNDS | IND TECH RES INST (TW) | 2009-10-14 | — | — | EP | disclosed |
| EP-1768943-B1 | PROCESS FOR PREPARING ENANTIOMERICALLY PURE 1,1'-SPIROBIINDANE-6,6'-DIOL DERIVATIVES | IND TECH RES INST (CN) | 2008-12-17 | — | — | EP | disclosed |
| US-7214834-B2 | Process for preparing enantiomerically pure 1,1′-spirobiindane-6,6′-diol derivatives | EASTMAN KODAK COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| US-7150900-B2 | Liquid-crystal compositions comprising chiral compounds | EASTMAN KODAK COMPANY (US) | 2006-12-19 | — | — | US | disclosed |
| US-20060020150-A1 | Process for preparing enantiomerically pure 1,1'-spirobiindane-6,6'-diol derivatives | EASTMAN KODAK COMPANY | 2006-01-26 | — | — | US | disclosed |
| US-20050127327-A1 | Liquid-crystal compositions comprising chiral compounds | EASTMAN KODAK COMPANY | 2005-06-16 | — | — | US | disclosed |
| US-4345096-A | 3-/P-OXYPHENYLALKYL/GLUTARIC ACID | E. R. SQUIBB & SONS, INC. (US) | 1982-08-17 | — | — | US | disclosed |
| US-4230621-A | TRACERS, HYDROXYPHENYLGLUTARIC ACID DERIVATIVES | E. R. SQUIBB & SONS, INC. (US) | 1980-10-28 | — | — | US | disclosed |
| US-4221725-A | CHEMICAL INTERMEDIATE | E. R. SQUIBB & SONS, INC. (US) | 1980-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020150-A1 | Process for preparing enantiomerically pure 1,1'-spirobiindane-6,6'-diol derivatives | HSD11B1, PKD1, REN | CALM1 3546/4885IGF1R 3832/4885ALOX15 1117/4885 |
| US-20220213026-A1 | SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | CALM1 4011/4885IGF1R 1038/4885ALOX15 1073/4885 |
| US-12030835-B2 | Substituted amide compounds useful as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | CALM1 4011/4885IGF1R 1038/4885ALOX15 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.